PRVB News and Press, Provention Bio Inc. From 01/08/20

Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...

OLDWICK, N.J. , Jan. 8, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt b...

The top 10 stocks of 2019 are an interesting group. You might think tech stocks would dominate the upper echelon of equities, but you'd be wrong. As we saw in the IPO market , individual healthcare stocks actually had the strongest returns last year. Seven biotech companies made our list, inc...

Like Making Money With Penny Stocks? These Won Big This Year Investing in penny stocks has often proven to be the best way in which people can generate enormous returns within a short period of time. So, the interest in these stocks has always been high. Every year, certain penny stocks prov...

China Rapid Finance (NYSE: XRF ) +61% . More news on: China Rapid Finance Limited, NewLink Genetics Corporation, Assertio Therapeutics, Inc., Stocks on the move, Read more ...

Provention Bio (NASDAQ: PRVB ) perks up  5%  premarket on modest volume in reaction to its announcement that it continues to expect to start its rolling U.S. marketing application in mid-2020 for lead candidate PRV-031 (teplizumab) for the prevention or delay of type 1 diabetes (...

OLDWICK, N.J. , Dec. 12, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it completed a Type B multidisciplinary meeting with the U.S. Food and...

The back half of 2019 was a turbulent ride for small cap biotech stocks largely due to an oversupply of shares via an onslaught of capital raises and IPO’s in the space, coupled with pre-election rhetoric out of Washington threatening drug price regulation. Source: StockCharts.com...

One promising area for biotech investors looking for growth is the diabetes market. More than 425 million adults around the world have been diagnosed with the condition, a figure that will only continue to grow over the coming years. Because diabetes has a relatively low mortality rate and an i...

Provention Bio, Inc. (PRVB) Q3 2019 Earnings Conference Call November 5, 2019 04:30 PM ET Company Participants Sam Martin - Investor Relations Andrew Drechsler - Chief Financial Officer Ashleigh Palmer - Co-Founder and Chief Executive Officer Francisco Leon - Co-Founder and Chi...